HORIZONS-AMI Trial

Summary: Evaluated bivalirudin versus unfractionated heparin with abciximab during ST elevation MI at 30 days. Bivalirudin had fewer adverse events, less major bleeding and reduced death from cardiac causes. There was no difference in major adverse cardiac events (MACE) or stent thrombosis at 30 days. Subsequent follow-up confirmed at 1 and 3 years the benefit of bivalirudin.

Paclitaxel stent versus bare metal stent was also evaluated for efficacy. Paclitaxel stents had significantly reduced ischemia driven revascularization at 1 and 3 years compared to bare metal stents. There is no mortality benefit and no difference in stent thrombosis.

Original Publication:

N Engl J Med. 2008 May 22;358(21):2218-30.

Lancet. 2009 Oct 3;374(9696):1149-59.

N Engl J Med. 2009 May 7;360(19):1946-59.

Lancet. 2011 Jun 25;377(9784):2193-204.
 

Eponym: Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction